Search results for "Diabetology"

showing 10 items of 31 documents

Atherogenic dyslipidemia and oxidative stress: a new look

2009

Although results from in vitro studies and clinical trials demonstrate strong associations between oxidative stress and cardiovascular risk, to date still no convincing data are available to suggest that treatment with antioxidants might reduce vascular events. Oxidative modifications of low-density lipoproteins (LDL) represent an early stage of atherosclerosis, and small, dense LDL are more susceptible to oxidation than larger, more buoyant particles. Oxidized LDL are independent predictors of subclinical and clinical atherosclerosis. Recent studies suggested that novel therapeutic strategies may take into account the removal of such particles from circulation. Future research is required …

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthOxidative phosphorylation030204 cardiovascular system & hematology2704 Biochemistry (medical)medicine.disease_causeAtherogenic dyslipidemia oxidative stressCoronary artery disease03 medical and health sciences2737 Physiology (medical)0302 clinical medicinePhysiology (medical)Internal medicineHumansMedicineDyslipidemias030304 developmental biologySubclinical infectionchemistry.chemical_classification0303 health sciencesReactive oxygen speciesAtherogenic dyslipidemiabusiness.industryVascular diseaseBiochemistry (medical)Public Health Environmental and Occupational HealthAtherogenic dyslipidemia2739 Public Health Environmental and Occupational HealthGeneral MedicineAtherosclerosismedicine.disease3. Good healthLipoproteins LDLOxidative StressEndocrinologychemistrybusinessOxidized ldlOxidative stressTranslational Research
researchProduct

Post-prandial alterations in LDL size and subclasses in patients with growth hormone deficiency

2008

Abstract Objective Several studies have suggested that lipoproteins generated during the post-prandial phase are highly atherogenic, with modifications in low-density lipoproteins (LDL) size and density. In the present study we assessed post-prandial variations in LDL size and subclasses in patients with growth hormone deficiency (GHD). Design We studied in 12 hypopituitary patients with GHD and 10 healthy control subjects matched for gender, age and body mass index (BMI) post-prandial variations after a standardized meal consisting of 35% fat, 45% carbohydrate and 20% of protein (Clinutren Mix ® , Nestle) and containing calories corresponding to 1/3 of estimated basal metabolic rate. Blood…

AdultMalemedicine.medical_specialtyCalorieEndocrinology Diabetes and Metabolism10265 Clinic for Endocrinology and Diabetology610 Medicine & healthPilot ProjectsHypopituitarismSubclassGrowth hormone deficiencyEndocrinologyInternal medicinemedicineHumansLipoproteinGel electrophoresisMealbusiness.industryMiddle AgedCarbohydratePost-prandialPostprandial Periodmedicine.diseaseSmall dense LDL1310 EndocrinologyLipoproteins LDL2712 Endocrinology Diabetes and MetabolismEndocrinologyCase-Control StudiesGrowth HormoneBasal metabolic rateGrowth hormone deficiencyFemalelipids (amino acids peptides and proteins)businessBody mass indexGrowth Hormone & IGF Research
researchProduct

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

2010

The ADA and the EASD recently published a consensus statement for the medical management of hyperglycaemia in patients with type 2 diabetes. The authors advocate initial treatment with metformin monotherapy and lifestyle modification, followed by addition of basal insulin or a sulfonylurea if glycaemic goals are not met (tier 1 recommendations). All other glucose-lowering therapies are relegated to a secondary (tier 2) status and only recommended for selected clinical settings. In our view, this algorithm does not offer physicians and patients the appropriate selection of options to individualise and optimise care with a view to sustained control of blood glucose and reduction both of diabe…

cardiovascular riskGlucose-lowering therapyEndocrinology Diabetes and MetabolismeducationSocieties Medical/standardsMEDLINE10265 Clinic for Endocrinology and DiabetologyHypoglycemic Agents/therapeutic use610 Medicine & healthType 2 diabetesHyperglycemia/drug therapyLifestyle modificationRisk FactorsDiabetes mellitusTier 2 networkADA Consensus StatementmedicineInternal MedicineInitial treatmentHyperglycaemiaHumansIn patientFor Debatealgorithmbusiness.industrynutritional and metabolic diseasesType 2 diabetesmedicine.diseaseCardiovascular riskUnited StatesMetforminEASD consensus statementglucose-lowering therapyAlgorithmEurope2712 Endocrinology Diabetes and Metabolism2724 Internal Medicine*AlgorithmsDiabetes Mellitus Type 2/complications/*drug therapytype 2 diabetesbusinessAlgorithmCardiovascular Diseases/prevention & controlhyperglycaemiamedicine.drug
researchProduct

Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.

2009

OBJECTIVE: Dyslipidaemia is very common in patients with polycystic ovary syndrome (PCOS) but, beyond plasma lipids, atherogenic lipoprotein (Lp) and apolipoprotein (apo) alterations are still ill defined. DESIGN: We measured concentrations of apoB, Lp(a) and small, dense low-density lipoprotein (LDL) in 42 patients with PCOS [age: 28 +/- 7 years, body mass index (BMI): 27 +/- 5 kg/m(2)] vs. 37 age- and BMI-matched healthy controls. METHODS: Elevated Lp(a) levels considered were those > 30 mg/dl while elevated apoB concentrations were those > 100 g/l. RESULTS: Polycystic ovary syndrome showed increased triglycerides levels (p = 0.0011) and lower high-density lipoprotein (HDL)-cholesterol co…

Adultmedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein B10265 Clinic for Endocrinology and Diabetology610 Medicine & health2700 General MedicineSettore MED/13 - EndocrinologiaBody Mass Indexchemistry.chemical_compoundYoung AdultRisk FactorsInternal medicinemedicinedyslipidemia lipoproteins polycystic ovary syndromeHumansProspective cohort studyApolipoproteins BDyslipidemiasbiologyCholesterolbusiness.industryVascular diseaseCase-control studynutritional and metabolic diseasesGeneral MedicineCholesterol LDLmedicine.diseasePolycystic ovaryEndocrinologychemistry10036 Medical ClinicCardiovascular DiseasesCase-Control Studiesbiology.proteinlipids (amino acids peptides and proteins)FemalebusinessBody mass indexLipoproteinLipoprotein(a)Polycystic Ovary SyndromeInternational journal of clinical practice
researchProduct

Impact of Metabolic Status on the Course of Atrial Fibrillation

2018

Abstract Background and aims: Metabolic syndrome (MS) might influence the course of atrial fibrillation (AF) similarly to diabetes (DM). Aim of this research is to evaluate the quality of life, disease burden and medication adherence of patients with different metabolic states. Material and methods: A cross-sectional study of Latvian Center of Cardiology Arrhythmology Department patients with AF, sorting patients in 3 categories according to the National Institutes for Health guidelines criteria for MS. Results: From 133 patients, 51 were in metabolically healthy (MH) group, 58 in MS group and 24 had DM. Average age was 62.59 in MH, 67.59 in MS and 66.25 in DM group. Most common form of AF …

medicine.medical_specialtyobesitybusiness.industrySpecialties of internal medicineAtrial fibrillation030204 cardiovascular system & hematologymedicine.diseasemetabolic syndrome03 medical and health sciences0302 clinical medicineRC581-951diabetes mellitusEndocrinology diabetologymedicineatrial fibrillation030212 general & internal medicineIntensive care medicinebusinessRomanian Journal of Diabetes Nutrition and Metabolic Diseases
researchProduct

Is diabetes the cost to pay for a greater cardiovascular prevention?

2010

The recent JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) trial is another study providing evidence about the effectiveness of statin therapy in reducing cardiovascular risk. Yet, in this study significantly higher glycated hemoglobin levels and incidence rates of diabetes were observed in persons treated with rosuvastatin than the placebo group. It should be noted that adverse effects on glucose metabolism have already been reported, albeit rarely, in previous trials with statins. Although the exact mechanisms involved are unknown, it seems that statins may deteriorate glycemic control by decreasing different metabolites,…

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthDiabete2705 Cardiology and Cardiovascular Medicinechemistry.chemical_compoundDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumansRosuvastatinRisk factorRosuvastatin CalciumAdverse effectGlycemicSulfonamidesbusiness.industryPreventionIncidence (epidemiology)Statinsnutritional and metabolic diseasesCardiovascular riskmedicine.diseaseFluorobenzenesRosuvastatin CalciumEndocrinologyPyrimidineschemistryCardiovascular DiseasesAtherosclerosilipids (amino acids peptides and proteins)Glycated hemoglobinHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance ?

2009

Summary Background:  Statins have emerged as the global leader in pharmacologic therapy for dyslipidaemia, and rosuvastatin has demonstrated clinical efficacy as well as safety in several clinical trials and postmarketing analyses. Aim:  The present article reviewed the effects of rosuvastatin on the quantity and the quality of low-density lipoproteins (LDL). Methods:  We searched for and reviewed all the available evidence in a systematic way. A literature search (by Medline and Scopus) was performed using the following headings: ‘LDL-cholesterol’, ‘LDL size’, ‘LDL subclasses’, ‘small dense LDL’, ‘apolipoprotein B, apo B’ and ‘rosuvastatin’ up to 11 November 2008. The authors also manually…

medicine.medical_specialtyApolipoprotein BHypercholesterolemia10265 Clinic for Endocrinology and DiabetologyMEDLINE610 Medicine & health2700 General MedicinePharmacotherapyInternal medicineDiabetes mellitusmedicineHumansLDL-cholesterolRosuvastatinClinical significanceRosuvastatin CalciumAgedClinical Trials as TopicSulfonamidesbiologybusiness.industrynutritional and metabolic diseasesCholesterol LDLGeneral Medicinemedicine.diseaseFluorobenzenesPrimary PreventionClinical trialPyrimidinesTreatment OutcomeEndocrinologyCardiovascular Diseasesrosuvastatin LDL-cholesterol type-2 diabetesHMG-CoA reductasebiology.proteinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessmedicine.drug
researchProduct

Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome

2009

Summary Objective  Small, dense low-density lipoproteins (LDL) are a feature of the metabolic syndrome (MS) but their predictive role still remains to be established. We performed a 2-year follow-up study in 124 subjects with MS (63 ± 6 years), as defined by the American Heart Association/National Heart, Lung and Blood Institute guidelines, to assess clinical and biochemical predictors of cerebro- and cardio-vascular events. Methods and results  Beyond traditional cardiovascular risk factors, we measured LDL size and subclasses by gradient gel electrophoresis. Clinical events were registered in the 25% of subjects. At univariate analysis subjects with events had increased prevalence of elev…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism10265 Clinic for Endocrinology and Diabetology610 Medicine & healthCerebroCoronary artery diseaseEndocrinologyPredictive Value of TestsRisk FactorsInternal medicinemedicineHumansFamily historyLow-density lipoproteins (LDL metabolic syndromeAgedMetabolic SyndromeUnivariate analysisbusiness.industryMiddle Agedmedicine.disease1310 EndocrinologyLipoproteins LDL2712 Endocrinology Diabetes and MetabolismEndocrinologymedicine.anatomical_structureSmall dense low-density lipoproteins cardio events cerebro-vascular events the metabolic syndromeCardiovascular DiseasesPredictive value of testsCirculatory systemFemaleMetabolic syndromebusinessBlood vesselFollow-Up Studies
researchProduct

Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype

2017

BACKGROUND: Dyslipidemia is common in women with polycystic ovary syndrome (PCOS) but its prevalence in different PCOS phenotypes is still largely unknown. METHODS: We measured plasma lipids and lipoproteins in 35 anovulatory PCOS (age: 25 ± 6 years, BMI: 28 ± 6 kg/m2), 15 ovulatory PCOS (age: 30 ± 6 years, BMI: 25 ± 3 kg/m2) and 27 healthy women (controls) age- and BMI-matched with ovulatory PCOS. PCOS was diagnosed by the presence of clinical or biologic hyperandrogenism associated with chronic anovulation and/or polycystic ovaries at ultrasound. In women with normal menses chronic anovulation was indicated by low serum progesterone levels (<9.54 nmol/l) during midluteal phase (days 21…

AdultOvulationmedicine.medical_specialtySettore MED/09 - Medicina Internaendocrine system diseases10265 Clinic for Endocrinology and Diabetology610 Medicine & healthBiologyAnovulationchemistry.chemical_compoundInsulin resistancepolycystic ovary syndrome lipids lipoproteins cardiovascular riskRisk FactorsInternal medicinemedicineHumansTriglyceridesTestosteroneDyslipidemiasTriglycerideRehabilitationHyperandrogenismObstetrics and Gynecologynutritional and metabolic diseases2729 Obstetrics and GynecologyCholesterol LDL2743 Reproductive MedicineAtherosclerosismedicine.diseasePolycystic ovarySettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsCholesterolEndocrinologyReproductive Medicinechemistry10036 Medical ClinicFemalelipids (amino acids peptides and proteins)DyslipidemiaPolycystic Ovary SyndromeLipoprotein
researchProduct

Are we confident that final‐year medical students know at least basics about diabetes?: A preliminary report from the multicenter, survey‐based Diabe…

2021

Abstract Background We present the results of the pilot study of a multinational “Diabetes Know‐Me” project investigating knowledge regarding diabetes of medical students. This is the first collaborative project of the ISPAD JENIOUS group. Methods Students of the final year of medical studies from six countries answered a 25‐question survey regarding basic knowledge concerning diabetes (1091 surveys handed out, response rate 86%). Results Among the responders (58% female) 90% confirmed attending diabetology classes; 11% planned to specialize in diabetology. There were significant differences between countries in the median score of correct answers ranging from 10/25 to 22/25. Attending diab…

Malemedicine.medical_specialtydiabetes knowledgeEndocrinology Diabetes and Metabolismcurriculummedical students030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineBasic knowledgePreliminary reportSurveys and QuestionnairesDiabetes mellitusDiabetes MellitusInternal MedicinemedicineHumans030212 general & internal medicineCurriculummedical studiesResponse rate (survey)Median scorediabetesEducation Medicalbusiness.industryDiabetologymedicine.diseaseReviews and CommentariesFamily medicinePediatrics Perinatology and Child HealthMulticenter surveyFemaleClinical CompetencebusinessPediatric Diabetes
researchProduct